HONG KONG – Chinese biotech company Harbour Biomed Therapeutics Ltd. has entered a collaboration and licensing agreement with South Korea's Hanall Biopharma Co. Ltd. for novel biologics. Under the agreement, Harbour, of Shanghai, will have the rights to develop, manufacture and commercialize HL-161 and HL-036 for the Greater China market, which includes the territories of Hong Kong, Macau and Taiwan.